- 30 April 2018
- Available Seats:
The attendee will be able to:
- Describe two (2) benefits each for the clinical site, sponsor and patient of a direct to patient trial.
- Identify at least two (2) risks for sponsors conducting direct to patient trials and develop effective mitigation strategies for these risks.
- List no fewer than 3 study characteristics that influence a decision to use a direct to patient strategy and why they should be considered.